|Day Low/High||172.71 / 172.96|
|52 Wk Low/High||86.00 / 172.98|
Mega deals from strategic players across a variety of industries pushed first-quarter deals to the highest value since 2007.
The recent bid by Mylan to acquire Perrigo offers the latest example of pharma companies that have been seeking growth opportunities.
Mylan made public on Wednesday that it had made a proposal to acquire generic drugmaker Perrigo in a deal valued at $205 per share in cash and stock.
The stock markets in the United States gained as investors evaluate the timing of interest rate hikes following the release of economic data that missed expectations. The markets also benefited amid c...
Stocks held onto session highs Monday ahead of the Federal Reserve's two-day policy meeting beginning on Tuesday.
Stocks hold onto session highs by midafternoon Monday ahead of the Federal Reserve's two-day policy meeting that begins Tuesday.
Valeant comes out on top, following a competing bid from Endo International for the gastrointestinal drugmaker Salix.
Stocks surge on Monday, following European and Asian markets higher.
Shares of Salix Pharmaceuticals (SLXP) are up as Valeant Pharmaceuticals increased the offer price to acquire all of the company to $173 from $158 per share in cash.
Stock futures are kicking the week off in better fashion than the past few trading sessions, though worries ahead of Wednesday's Federal Reserve policy statement linger.
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSX:VRX) and Salix Pharmaceuticals, Ltd.
Shares of Salix Pharmaceuticals (SLXP) were down as Valeant Pharmaceuticals (VRX) reportedly plans to raise its offer for the company.
U.S. stock futures are down slightly on Friday, as investors anticipate consumer sentiment data and next week's Federal Reserve Open Market Committee meeting.
Stocks with insider trader activity include EQIX, SLXP and ISR
Stock futures post modest gains on Thursday morning in an attempted recovery after two days of losses which wiped out Wall Street's year-to-date gains.
Endo International threw a wrench in the Valeant Pharmaceuticals' $10 billion buyout agreement for Salix Pharmaceuticals, swooping in with a higher buyout offer.
They get an A for effort, but stocks never managed to recover from Tuesday's brutal selloff.
Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP) ("Salix" or the "Company") today confirmed that it has received an unsolicited proposal from Endo International plc ("Endo") to acquire all of the outstanding shares of common...
Shares of Salix Pharmaceuticals (SLXP) are up after Endo International (ENDP) made a takeover offer for the company, seeking to wrest it from Valeant Pharmaceuticals (VRX).
Trade-Ideas LLC identified Salix Pharmaceuticals (SLXP) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate